Extract
Fractional exhaled nitric oxide (FeNO) is a single-breath test used in asthma diagnosis and management. Whilst a number of studies in mild to moderate asthma have demonstrated excellent repeatability of FeNO by assessing intra-device reproducibility from consecutive blows [1–3], the between-session and diurnal variability have been inconsistent [4–9]. Asthma is a highly variable disease. The excessive diurnal variability in airflow obstruction is a marker for disease severity, poor control and mortality. Diurnal variability of FeNO is also a predictor for poor asthma control [8]. We have demonstrated that FeNO has a significant time-of-the-day difference with a median of 12 parts per billion (ppb) between peak and trough readings within a 24-hour cycle in stable mild/moderate asthma [10]; whether this same-day variation is clinically significant in the diagnosis and management of asthma remains unclear. FeNO has been readily used in the monitoring of severe asthma, but its same-day reproducibility as a single-breath test is unknown in this group.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Wang has nothing to disclose.
Conflict of interest: Dr. Alahmadi has nothing to disclose.
Conflict of interest: Dr. Niven has nothing to disclose.
Conflict of interest: Stephen J Fowler has no conflict of interest
- Received September 4, 2020.
- Accepted January 11, 2021.
- ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org